The Journal of Practical Medicine >

2023 , Vol. 39 >Issue 23: 3137 - 3142

DOI: https://doi.org/10.3969/j.issn.1006-5725.2023.23.020

Reviews

Progress in genetic research on metastatic pheochromocytoma and paraganglioma

  • Yuanjian LIAO ,
  • Jingjing YAO ,
  • Mingshun ZUO ,
  • Hongchuan CHEN ,
  • Te XU ,
  • Neng. ZHANG
Expand
  • *.Department of Urology，Zunyi Medical University Affiliated Hospital，Zunyi 563000，China

Received date: 2023-07-24

  Online published: 2024-01-08

Fold

Abstract

Metastatic pheochromocytoma and paraganglioma （MPPGL） is a rare neuroendocrine tumour in which genetic factors play an important role. In recent years， with the continuous progress of genetic testing technology， more and more susceptibility genes have been proved to be associated with MPPGL， making early identification of MPPGL possible. Recent studies have shown that genes associated with the development of MPPGL include SDHA， SDHB， SDHC， SDHD， SDHAF2， FH， MDH2， VHL， IDH1， PDH1/2， SLC25A11， GOT2， DLST， CSDE1， MAML3， H3F3A， MERTK， PCDHGC3， and KIF1B， with SDHA， SDHB， SDHC， SDHD， and SDHAF2 being the common pathogenic genes. Potential mutations affect the clinical manifestations of MPPGL， such as malignant potential and genetic prediction， which can help to better understand the clinical course and treat accordingly. Genetic testing for pheochromocytomas and paragangliomas allows for early detection of genetic syndromes and facilitates close follow-up of high-risk patients. This article provides a review of the progress of research on susceptibility genes identified in MPPGL in recent years， with a view to providing a certain theoretical basis for further related research.

Key words： metastatic pheochromocytoma; metastatic paraganglioma; genetics; genes

Cite this article

Yuanjian LIAO , Jingjing YAO , Mingshun ZUO , Hongchuan CHEN , Te XU , Neng. ZHANG . Progress in genetic research on metastatic pheochromocytoma and paraganglioma[J]. The Journal of Practical Medicine, 2023 , 39(23) : 3137 -3142 . DOI: 10.3969/j.issn.1006-5725.2023.23.020

References

1 ILANCHEZHIAN M， JHA A， PACAK K， et al. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma［J］. Curr Treat Options Oncol， 2020，21（11）：85.
2 JHAWAR S， ARAKAWA Y， KUMAR S， et al. New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications［J］. Cancers （Basel）， 2022，14（3）：594.
3 KOHLENBERG J， WELCH B， HAMIDI O， et al. Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma［J］. Cancers （Basel）， 2019，11（2）：195.
4 REMACHA L， PIRMAN D， MAHONEY C E， et al. Recurrent germline DLST mutations in individuals with multiple pheochromocytomas and paragangliomas［J］. Am J Hum Genet， 2019，104（4）：651-664.
5 N?LTING S， BECHMANN N， TAIEB D， et al. Personalized Management of Pheochromocytoma and Paraganglioma［J］. Endocr Rev， 2022，43（2）：199-239.
6 GUL A E， KESER S H， BARISIK N O， et al. Succinate Dehydrogenase Complex Iron Sulfur Subunit B （SDHB） Immunohistochemistry in Pheochromocytoma， Head and Neck Paraganglioma， Thoraco-Abdomino-Pelvic Paragangliomas： Is It a Good Idea to Use in Routine Work？ ［J］.Asian Pac J Cancer Prev，2021，22（6）：1721-1729.
7 ANDREWS K A， ASCHER D B， PIRES D E V， et al. Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB， SDHC and SDHD［J］. J Med Genet， 2018，55（6）：384-394.
8 JOCHMANOVA I， WOLF K I， KING K S， et al. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations［J］. J Cancer Res Clin Oncol， 2017，143（8）：1421-1435.
9 PAMPORAKI C， HAMPLOVA B， PEITZSCH M， et al. Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas［J］. J Clin Endocrinol Metab， 2017，102（4）：1122-1132.
10 PULIANI G， SESTI F， FEOLA T， et al. Natural History and Management of Familial Paraganglioma Syndrome Type 1： Long-Term Data from a Large Family［J］. J Clin Med，2020，9（2）：588.
11 BAYLEY J P， BAUSCH B， RIJKEN J A， et al. Variant Type Is Associated With Disease Characteristics in SDHB， SDHC and SDHD-Linked Phaeochromocytoma-Paraganglioma［J］. J Med Genet， 2020，57（2）：96-103.
12 CASCóN A， REMACHA L， CALSINA B， et al. Pheochromocytomas and Paragangliomas： Bypassing Cellular Respiration［J］.Cancers （Basel）， 2019，11（5）：683.
13 LEE H， JEONG S， YU Y， et al. Risk of metastatic pheochromocytoma and paraganglioma in SDHx mutation carriers： a systematic review and updated meta-analysis［J］. J Med Genet， 2020，57（4）：217-225.
14 WILLIAMS S T， CHATZIKYRIAKOU P， CARROLL P V， et al. SDHC phaeochromocytoma and paraganglioma： A UK-wide case series［J］. Clin Endocrinol （Oxf），2022，96（4）：499-512.
15 CASCóN A， CALSINA B， MONTEAGUDO M， et al. Genetic bases of pheochromocytoma and paraganglioma［J］. J Mol Endocrinol，2023，70（3）：e220167.
16 MANIAM P， ZHOU K， LONERGAN M， et al. Pathogenicity and penetrance of germline SDHA variants in pheochromocytoma and paraganglioma （PPGL）［J］. J Endocr Soc， 2018，2：806-816.
17 BAUSCH B， SCHIAVI F， NI Y， et al. European-American-Asian Pheochromocytoma-Paraganglioma Registry Study Group. Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA， TMEM127， MAX， and SDHAF2 for Gene-Informed Prevention［J］. JAMA Oncol， 2017，3（9）：1204-1212.
18 SOLAIMUTHU B， LICHTENSTEIN M， HAYASHI A， et al. Depletion of Fumarate Hydratase， an Essential TCA Cycle Enzyme， Drives Proliferation in a Two-Step Model［J］. Cancers （Basel）， 2022，14（22）：5508.
19 RICHTER S， GARRETT T J， BECHMANN N， et al. Metabolomics in paraganglioma： applications and perspectives from genetics to therapy［J］. Endocr Relat Cancer， 2023，30（6）：e220376.
20 KUO M J M， NAZARI M A， JHA A， et al. Pediatric Metastatic Pheochromocytoma and Paraganglioma： Clinical Presentation and Diagnosis， Genetics， and Therapeutic Approaches［J］. Front Endocrinol （Lausanne）， 2022，13：936178.
21 LENDERS J W M， KERSTENS M N， AMAR L， et al. Genetics， diagnosis， management and future directions of research of phaeochromocytoma and paraganglioma： a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension［J］. J Hypertens， 2020，38（8）：1443-1456.
22 JOCHMANOVA I， PACAK K. Genomic Landscape of Pheochromocytoma and Paraganglioma［J］. Trends Cancer， 2018，4（1）：6-9.
23 ZHANG J， JIANG J， LUO Y， et al. Molecular Evaluation of a Sporadic Paraganglioma With Concurrent IDH1 and ATRX Mutations［J］. Endocrine， 2018， 61：216-223.
24 游静茹，杨璐，崔小丽，等. 急性髓系白血病中表观遗传学异常的研究进展［J］. 实用医学杂志， 2023，39（10）：1316-1319.
25 LACHOWIEZ C A， REVILLE P K， KANTARJIAN H， et al. Contemporary outcomes in IDH-mutated acute myeloid leukemia： The impact of co-occurring NPM1 mutations and venetoclax-based treatment［J］. Am J Hematol， 2022，97（11）：1443-1452.
26 周亚琼，严鹏，张华敏，等. 腹部副神经节瘤的临床特征及长期预后分析［J］. 实用医学杂志， 2021，37（21）：2743-2747.
27 BUFFET A， MORIN A， CASTRO-VEGA L J， et al. Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier SLC25A11 Gene Confer a Predisposition to Metastatic Paragangliomas［J］. Cancer Res， 2018，78（8）：1914-1922.
28 REMACHA L， COMINO-MéNDEZ I， RICHTER S， et al. Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer-Predisposing Mutations in Pheochromocytomas and Paragangliomas［J］. Clin Cancer Res， 2017，23（20）：6315-6324.
29 REMACHA L， PIRMAN D， MAHONEY C E， et al. Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paraganglionas［J］. Am J Hum Genet， 2019，104（4）：651-664.
30 FISHBEIN L， LESHCHINER I， WALTER V， et al. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma［J］. Cancer Cell， 2017，31（2）：181-193.
31 TOLEDO R A， QIN Y， CHENG Z M， et al. Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas［J］. Clin Cancer Res， 2016，22（9）：2301-2310.
32 BERNARDO-CASTI?EIRA C， VALDéS N， CELADA L， et al. Epigenetic deregulation of protocadherin PCDHGC3 in pheochromocytomas/paragangliomas associated with SDHB mutations［J］. J Clin Endocrinol Metab， 2019，104：5673-5692.
33 MA X， LI M， TONG A， et al. Genetic and Clinical Profiles of Pheochromocytoma and Paraganglioma： A Single Center Study［J］. Front Endocrinol （Lausanne）， 2020，11：574662.
Options
Outlines

/

〈 〉